The AIM aAPC are synthetic nanoparticles, designed to convey the benefits of cellular therapy with pharmaceutical precision. These aAPC are highly flexible and can be modified as shown below, and loaded with a range of specific disease-associated antigens. The aAPC are manufactured with high reproducibility and used to generate an adoptive therapy or as a direct immunotherapy.
The ability to rapidly modify products which precisely target cells and desired actions makes the platform an ideal option for developing personalized treatments, for diseases where speed of development is critical and for developing combinations with other immune modulating or Standard of Care therapies.
Rapid Loading or Validation of Epitopes
The aAPC can be rapidly loaded with any set of antigen epitopes and quickly evaluated for specific tumors or infectious diseases of interest. Any HLA restricted epitope can be loaded on the aAPC and used to make an aAPC cocktail.
The AIM enrichment and expansion system can be used to validate predicted neo-antigens or epitopes which can be subsequently loaded onto aAPC.
Epitopes from the following antigens have been tested in pre/non-clinical models
Expanding Eligible Populations
The aAPC can be modified to expand eligible populations by changing Signal 1 (HLA) in a templated lego-like approach. The POC aAPC is constructed with HLA-A2, with additional options including HLA-A1, HLA-A11, HLA-A24, HLA-B7 which can be quickly developed.
Modifying “Go” or “Kill” Signals
The aAPC can be modified by changing Signal 2, providing the “Go” or “Kill” signal depending on desired mechanism, using our lego-like templated approach. A “Go” signal can be used for rapid positive selection to engage and activate target cells, while the “Kill” signal can be used to anergize or kill target cells. The POC aAPC is constructed with anti-CD28 which can be replaced other signals such as anti-41BB or anti-FAS depending on the precise action desired.
Targeting Immune Cell Types
The AIM Platform can be used to target other immune cells of choice across MHC Class 1, MHC Class II or CD1 molecules.
Any combination of modifications to the aAPC above can be configured in our lego-like templated approach. This unique feature of the AIM Platform enables fast early proof of concept using the research format and streamlining product development and evolution.